Michael Feld
Known title: EVP, Chief Revenue OfficerCIK: 0002034349
Associated companies
Transaction History
| BDX | ▼ Sell | Open Market | 165 | $31K | 8/26/2026 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 1,049 | $0 | 8/20/2026 | View on chart |
| BDX | ▼ Sell | Open Market | 75 | $12K | 7/27/2026 | View on chart |
| BDX | ▼ Sell | Open Market | 75 | $11K | 6/26/2026 | View on chart |
| BDX | ▼ Sell | Open Market | 75 | $11K | 5/26/2026 | View on chart |
| BDX | ▼ Sell | Open Market | 74 | $11K | 4/27/2026 | View on chart |
| BDX | ▼ Sell | Open Market | 75 | $12K | 3/26/2026 | View on chart |
| BDX | ▼ Sell | Open Market | 75 | $14K | 2/26/2026 | View on chart |
| BDX | ▼ Sell | Open Market | 75 | $15K | 1/26/2026 | View on chart |
| BDX | ▼ Sell | Open Market | 74 | $15K | 12/26/2025 | View on chart |
| BDX | ▼ Sell | Open Market | 75 | $15K | 12/1/2025 | View on chart |
| BDX | ▲ Buy | Grant | 8,829 | $0 | 11/26/2025 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 419 | $0 | 11/26/2025 | View on chart |
| BDX | ▼ Sell | Open Market | 57 | $11K | 10/27/2025 | View on chart |
| BDX | ▼ Sell | Open Market | 58 | $10K | 9/26/2025 | View on chart |
| BDX | ▼ Sell | Open Market | 57 | $11K | 8/22/2025 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 773 | $0 | 8/20/2025 | View on chart |
| BDX | ▲ Buy | Grant | 2,553 | $0 | 11/26/2024 | View on chart |
| BDX | ▲ Buy | Grant | 6,637 | $0 | 8/20/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%
The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.